The Efficacy of Tislelizumab Combined With S-1 in Patients With Residual Primary Lesions and Node-Negative Esophageal Squamous Cell Carcinoma After Neoadjuvant Immunochemotherapy Followed by Curative Resection: A Phase II, Multicenter Trial
To explore the safety and efficacy of Tegafur combined with tislelizumab in patients with esophageal squamous cell carcinoma with residual primary lesion and node-negative after radical resection following neoadjuvant immunotherapy combined with chemotherapy
⁃ Age 18-75 years old, gender is not limited;
⁃ Patients with esophageal squamous cell carcinoma with neoadjuvant immunotherapy combined with chemotherapy (radiotherapy was not planned during the study period);
⁃ Thoracic esophageal squamous cell carcinoma patients with residual pathologic primary site and lymph node positive (ypT1-4aN0M0) after surgery (8th UICC-TNM stage);
⁃ The operation was radical resection;
⁃ Physical status ECOG 0 \
• 1 score;
⁃ No local recurrence or distant metastasis was found in the examination before postoperative adjuvant treatment;
⁃ There were no contraindications of chemotherapy or immunotherapy in the evaluation of various organ functions;
⁃ Understand and sign the informed consent.